Amid Zolgensma crisis, Novartis gets a gene therapy boost as NICE embraces Luxturna
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! With the first gene therapy for blindness in the market, the door has been opened for a new wave of gene therapy treatments with the potential to cure genetic blindness. In December 2017, the FDA approved Luxturna, the first … Συνεχίστε να διαβάζετε Can Gene Therapy Become The Cure For Blindness?.
The gene therapy era has arrived. So have the challenges.
Novartis' SMA Gene Therapy Treatment Approved by FDA, Priced at $2.125 Million
World Parkinson’s Day: How Science Is Battling the Disease
Gene Therapy for Deafness, Autism Genes, Breakthroughs in Parkinson’s and ALS, and More
Novo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can’t launch until 2020
Gene therapy: how much will it cost patients?
Humble Beginnings: The Origin Story of Modern Biotechnology
After Earlier Dramatic Gene Therapy Collapse, uniQure's Hemophilia B Therapy Showing Promise